Pfizer Issues Response to Project Veritas Video

On Friday, Pfizer issued a response to the explosive Project Veritas video where Jordon Trishton Walker, Pfizer Director of Research and Development – Strategic Operations and mRNA Scientific Planning, claimed that the Pharma giant is exploring to mutate COVID-19 to continually profit off vaccines.

BREAKING: Pfizer Director Admits They Want To Mutate The Virus & Profit From It!

Quote:

Jordon Trishton Walker: “Why don’t we just mutate it ourselves so we could preemptively develop new vaccines, right?”

Project Veritas reported:

The Pfizer executive told a Veritas journalist about his company’s plan for COVID vaccines, while acknowledging that people would not like this information if it went public.

“One of the things we [Pfizer] are exploring is like, why don’t we just mutate it [COVID] ourselves so we could create — preemptively develop new vaccines, right? So, we have to do that. If we’re gonna do that though, there’s a risk of like, as you could imagine — no one wants to be having a pharma company mutating f**king viruses,” Walker said.

“From what I’ve heard is they [Pfizer scientists] are optimizing it [COVID mutation process], but they’re going slow because everyone is very cautious — obviously they don’t want to accelerate it too much. I think they are also just trying to do it as an exploratory thing because you obviously don’t want to advertise that you are figuring out future mutations,” he said.

“Don’t tell anyone. Promise you won’t tell anyone. The way it [the experiment] would work is that we put the virus in monkeys, and we successively cause them to keep infecting each other, and we collect serial samples from them.”

This is 100% “Gain of Function” research and it’s prohibited for obvious reasons.

Gain-of-Pfizer???https://t.co/ofC7ygHgfs

— DailyNoah.com (@DailyNoahNews) January 26, 2023

After the Project Veritas video, multiple GOP senators want answers from the Pharma giant.

Senator Ron Johnson (R-WI) demanded a congressional investigation into COVID-19 jab manufacturers.

Senator Ron Johnson Calls for Congressional Investigation Into ‘Vaccine Manufacturers’

Senator Marco Rubio (R-FL) sent a letter to Pfizer CEO Albert Bourla questioning the claims in the video.

GOP Senator Sends Letter to Pfizer CEO About Project Veritas Video

In their response, Pfizer denied allegations of conducting gain of function or directed evolution research.

BREAKING: Pfizer RESPONDS! https://t.co/PV4hHk73cM

— Project Veritas (@Project_Veritas) January 28, 2023

However, part of their response appears misleading.

One statement that stands out says: "In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells."

Pfizer's cheese really stinks!
🧀🧀🧀🧀🧀🧀#pfizerliedpeopledied #PfizerExposed https://t.co/naImAkZpol pic.twitter.com/KdO6TqePai

— Jikkyleaks 🐭 (@Jikkyleaks) January 28, 2023

https://twitter.com/kylenabecker/status/1619238460556206080

"We absolutely do not do this....now here's two paragraphs explaining that we actually do it, but call it a different name." -- Basically what it sounds like Pfizer is saying

— John Hawkins (@johnhawkinsrwn) January 28, 2023

The Pharma giant did not mention Jordon Trishton Walker in their response.

Read the full response from Pfizer:

Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight.

In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.  Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a vaccine update is required.

In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID™, Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID’s two components.  With a naturally evolving virus, it is important to routinely assess the activity of an antiviral.  Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus.  In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. In addition, in vitro resistance selection experiments are undertaken in cells incubated with SARS-CoV-2 and nirmatrelvir in our secure Biosafety level 3 (BSL3) laboratory to assess whether the main protease can mutate to yield resistant strains of the virus.  It is important to note that these studies are required by U.S. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world.

Fact-based information rooted in sound science is vitally important to overcoming the COVID-19 pandemic and Pfizer remains committed to transparency and helping alleviate the devastating burden of this disease.